A network meta-analysis of 14 major trials found that sotagliflozin was best for reducing heart attacks, strokes, and heart failure hospitalizations, while semaglutide and empagliflozin led for lowering death risk in type 2 diabetes patients.
HR 0.59 for heart failureSotagliflozin reduced heart failure hospitalization by 41% compared to the reference drug, ranking first among all 12 drugs analyzed
What the researchers found
Sotagliflozin ranked first for MACE (HR 0.76), heart failure hospitalization (HR 0.59), MI (HR 0.65), and stroke (HR 0.56). Empagliflozin and dapagliflozin led for kidney protection. Oral semaglutide and empagliflozin were best for all-cause death reduction.
Why it matters
Not all GLP-1 and SGLT2 drugs are equal for heart and kidney protection. This analysis gives clinicians evidence to match specific drugs to each patient's most important cardiovascular or renal risks.
The numbers in context
14 CVOTs; sotagliflozin MACE HR 0.76; HHF HR 0.59; MI HR 0.65; stroke HR 0.56; oral semaglutide and empagliflozin best for all-cause death
How the study worked
Bayesian network meta-analysis of 14 cardiovascular or renal outcome trials (CVOTs) from PubMed and Embase. Endpoints: MACE, stroke, MI, cardiovascular death, all-cause death, kidney function progression, and heart failure hospitalization. Hazard ratios with 95% CI and SUCRA rankings calculated.
Who was studied
Type 2 diabetes patients in cardiovascular or renal outcome trials
What this study cannot tell us
Network meta-analysis uses indirect comparisons between trials with different patient populations, follow-up durations, and baseline risks. Some drug-to-drug comparisons had wide confidence intervals. Sotagliflozin trials included heart failure patients, potentially inflating its cardiovascular benefit.
How to read the evidence
High evidence grade: network meta-analysis of 14 randomized cardiovascular/renal outcome trials, though indirect comparisons introduce some uncertainty.
When this study was published
Published in 2021. Additional cardiovascular outcome trials for GLP-1 and SGLT2 drugs have reported since, which may refine these rankings.
The bigger picture
As GLP-1 and SGLT2 drugs become standard diabetes care, understanding which specific drug best addresses each patient's risk profile enables precision medicine. This analysis supports a shift from class-level to drug-specific prescribing decisions.
Questions still open
- Would combining the best SGLT2 inhibitor with the best GLP-1 RA provide additive cardiorenal protection?
- Do the rankings change in patients without established cardiovascular disease?
- Why did ertugliflozin underperform compared to other SGLT2 inhibitors?
Common questions
Which diabetes drug is best for heart protection?
Are GLP-1 drugs or SGLT2 inhibitors better for kidneys?
Read the original research
Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
Medicine, 100(30), e26431
Citation
Duan, Xue-Yan; Liu, Shu-Yan; Yin, Dao-Gen. (2021). Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.. Medicine, 100(30), e26431. https://doi.org/10.1097/MD.0000000000026431